Montelukast Eg (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor type 1 (CysLT1). This inhibition prevents leukotrienes D4, C4 and E4 from triggering bronchoconstriction, mucus production and inflammatory cell activation, thereby stabilising the airways and reducing allergic responses.

The appropriate dose of Montelukast Eg is determined by a qualified healthcare professional based on the patient’s age, condition and response to therapy. Prescribers follow established clinical guidelines and adjust the regimen as needed.

Safety data for Montelukast in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy or breastfeeding should discuss potential risks and benefits with their physician before starting treatment.

To order Montelukast Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast is an oral leukotriene receptor antagonist, whereas inhaled corticosteroids are anti‑inflammatory agents delivered directly to the lungs. Montelukast is often used as an add‑on therapy or for patients who cannot tolerate inhaled steroids, but it does not replace the anti‑inflammatory potency of corticosteroids in severe asthma.

Montelukast Eg should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Montelukast Eg is taken orally, usually as a tablet, with or without food. The tablet is swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe allergic reactions such as rash, angioedema or anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and rare skin conditions such as Stevens‑Johnson syndrome. Any of these symptoms require immediate medical attention.

Montelukast Eg should be avoided in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Patients with severe hepatic impairment should use it only under close medical supervision, and it is not recommended for use in children under the age approved for the specific formulation.